Phase II, Open Label, Single-arm Study to Assess Safety and Efficacy of AZD9291 in Patients With Locally Advanced/Metastatic NSCLC Whose Disease Has Progressed With Previous EGFR TKI and Whose Tumours Are EGFR and T790M Mutation Positive

Trial Profile

Phase II, Open Label, Single-arm Study to Assess Safety and Efficacy of AZD9291 in Patients With Locally Advanced/Metastatic NSCLC Whose Disease Has Progressed With Previous EGFR TKI and Whose Tumours Are EGFR and T790M Mutation Positive

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2017

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AURA2
  • Sponsors AstraZeneca
  • Most Recent Events

    • 18 Oct 2017 Results of this and other trials (NCT01802632, NCT02094261 and NCT01544179) presented at the 18th World Conference on Lung Cancer
    • 05 Oct 2017 Planned End Date changed from 1 Nov 2017 to 16 May 2018.
    • 12 Sep 2017 Results (data cut off: 1 Nov, 2016; n = 411) of a pooled analysis from AURA extension AURA2 studies assessing overall survival in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with osimertinib, presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top